Acute Liver failure (ALF) is a life-threatening disease and is determined by coagulopathy (with INR ≥ 1.5) and hepatic encephalopathy as a result of severe liver injury in patients without preexisting liver disease. Since there are problems with liver transplantation including lack of donors, use of immunosuppressive drugs, and high costs of this process, new therapeutic approaches alongside current treatments are needed. The placenta is a tissue that is normally discarded after childbirth. On the other hand, human placenta is a rich source of mesenchymal stem cells (MSCs), which is easily available, without moral problems, and its derived cells are less affected by age and environmental factors. Therefore, placenta-derived mesenchymal stem cells (PD-MSCs) can be considered as an allogeneic source for liver disease. Considering the studies on MSCs and their effects on various diseases, it can be stated that MSCs are among the most important agents to be used for novel future therapies of liver diseases. In this paper, we will investigate the effects of mesenchymal stem cells through migration and immigration to the site of injury, cell-to-cell contact, immunomodulatory effects, and secretory factors in ALF.

中文翻译：

---

胎盘来源的间充质干细胞在急性肝衰竭中的应用前景。

急性肝功能衰竭（ALF）是一种危及生命的疾病，是由未患有肝病的严重肝损伤导致的凝血病（INR≥1.5）和肝性脑病决定的。由于肝移植存在问题，包括缺乏供体，使用免疫抑制药物以及该过程的高成本，因此需要新的治疗方法以及当前的治疗方法。胎盘是通常在分娩后丢弃的组织。另一方面，人胎盘是间充质干细胞（MSCs）的丰富来源，可以容易获得，没有道德问题，并且其衍生细胞受年龄和环境因素的影响较小。因此，胎盘来源的间充质干细胞（PD-MSCs）可以被认为是肝脏疾病的异体来源。考虑到对MSC及其对各种疾病的影响的研究，可以说MSC是最重要的药物，可用于未来肝病的新疗法。在本文中，我们将研究ALF中间充质干细胞通过迁移和迁移至损伤部位，细胞间接触，免疫调节作用和分泌因子的作用。